UMMS Affiliation

Department of Cancer Biology and the Cancer Center

Date

1-7-2006

Document Type

Article

Subjects

1-Phosphatidylinositol 3-Kinase; Adaptor Proteins, Signal Transducing; Animals; Antigens, CD29; CHO Cells; Cell Adhesion; Cricetinae; Cytoplasm; Humans; Insulin-Like Growth Factor II; Intracellular Signaling Peptides and Proteins; Laminin; Male; Mice; Phosphoproteins; Prostatic Neoplasms; Protein Phosphatase 2; Protein Structure, Tertiary; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Protein Tyrosine Phosphatases; RNA, Messenger; Transfection; Up-Regulation

Disciplines

Cancer Biology

Abstract

The interactions between cancer cells and the extracellular matrix (ECM) regulate cancer progression. The beta1C and beta1A integrins, two cytoplasmic variants of the beta1 integrin subfamily, are differentially expressed in prostate cancer. Using gene expression analysis, we show here that the beta1C variant, an inhibitor of cell proliferation, which is down-regulated in prostate cancer, up-regulates insulin-like growth factor-II (IGF-II) mRNA and protein levels. In contrast, beta1A does not affect IGF-II levels. We provide evidence that beta1C-mediated up-regulation of IGF-II levels increases adhesion to Laminin-1, a basement membrane protein down-regulated in prostate cancer, and that the beta1C cytoplasmic domain contains the structural motif sufficient to increase cell adhesion to Laminin-1. This autocrine mechanism that locally supports cell adhesion to Laminin-1 via IGF-II is selectively regulated by the beta1 cytoplasmic domain via activation of the growth factor receptor binding protein 2-associated binder-1/SH2-containing protein-tyrosine phosphatase 2/phosphatidylinositol 3-kinase pathway. Thus, the concurrent local loss of beta1C integrin, of its ligand Laminin-1, and of IGF-II in the tumor microenvironment may promote prostate cancer cell invasion and metastasis by reducing cancer cell adhesive properties. It is, therefore, conceivable that reexpression of beta1C will be sufficient to revert a neoplastic phenotype to a nonproliferative and highly adherent normal phenotype.

Rights and Permissions

Citation: Cancer Res. 2006 Jan 1;66(1):331-42. Link to article on publisher's site

DOI of Published Version

10.1158/0008-5472.CAN-05-2588

Related Resources

Link to article in PubMed

Journal Title

Cancer research

PubMed ID

16397247

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.